Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tadalafil

- PMLiVE

Adherence programme helps Janssen to PMEA success

Company picks up three awards including Company of the Year

National Institute for Health and Care Excellence NICE logo

NICE denies early use of Janssen’s Velcade

Draft guidance doesn't recommend expanded bone marrow cancer indication

- PMLiVE

Psoriasis care falling short says Janssen survey

Claims dermatologists in UK are failing to refer to recommended clinical guidelines

- PMLiVE

Janssen submits blood cancer drug in EU

Seeks EMA approval for ibrutinib

Actelion HQ Switzerland

Actelion gets US green light for new PAH drug Opsumit

Approval will help reduce impact of generic competition for Tracleer

- PMLiVE

Buoyant pharma sales drive J&J’s Q3 results

Defies downturn with European growth of 12 per cent

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

- PMLiVE

European R&D investment “stagnating”

Report says health research spend was flat in 2011

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Janssen expands its ‘mobile health manager’

Add family support option to adherence campaign

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links